acolbifene
Small moleculeexperimental
Acolbifene is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00853996)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorINHIBITOR
Estrogen receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21.Cl- Mol. weight
- 494.03 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAcolbifene ↗
- ChEMBLCHEMBL2105965 ↗
Also known as
- acolbifene
- acolbifene hcl
- acolbifene hcl
- acolbifene hydrochloride
- acolbifene hydrochloride
- acolbifene hydrochloride
- sch-57068 hcl
- sch-57068 hcl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00853996 | Phase 2 | Feb 1, 2009 | National Cancer Institute (NCI), University of Kansas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2009 |
2 organizations
Page 1 / 1